1
|
Drumez E, Richez C, Bebear L, Herasse M, Flipo RM, Marotte H, Georgin-Lavialle S, Seror R, Pertuiset E, Avouac J, Chazerain P, Roux N, Pham T, Dernis E, Uzunhan Y, Servettaz A, El Mahou S, Cacoub P, Hamidou M, Fautrel B, Thomas T, Hachulla E. Comparing COVID-19 disease severity in patients with rheumatic and inflammatory diseases between the first and the subsequent waves. Joint Bone Spine 2023; 90:105605. [PMID: 37399939 DOI: 10.1016/j.jbspin.2023.105605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 06/07/2023] [Accepted: 06/21/2023] [Indexed: 07/05/2023]
Affiliation(s)
- Elodie Drumez
- Department of Biostatistics, CHU of Lille, Lille, Hauts-de-France, France
| | - Christophe Richez
- CNRS, ImmunoConcEpT, UMR 5164, Department of Rheumatology, University of Bordeaux, CHU of Bordeaux, 33000 Bordeaux, France.
| | - Louis Bebear
- Department of Rheumatology, CHU of Bordeaux, 33000 Bordeaux, France
| | - Muriel Herasse
- Filière des maladies auto-immunes et auto-inflammatoires rares, hôpital Huriez, centre hospitalier universitaire de Lille, Lille, France
| | - René-Marc Flipo
- Service de rhumatologie, université de Lille, CHU de Lille, Lille, France
| | - Hubert Marotte
- Inserm, SAINBIOSE U1059, service de rhumatologie, Mines Saint-Étienne, université Jean-Monnet Saint-Étienne, CHU de Saint-Étienne, 42023 Saint-Étienne, France
| | - Sophie Georgin-Lavialle
- Internal Medicine Department, Tenon Hospital, Sorbonne University, AP-HP, 4, rue de la Chine, 75020 Paris, France; National Reference Center for Autoinflammatory Diseases and AA Amyloidosis (CEREMAIA), Tenon Hospital, Paris, France
| | - Raphaèle Seror
- Inserm UMR 1184, service de rhumatologie, Centre de référence des maladies auto-immunes systémiques rares, hôpital Bicêtre, université Paris-Saclay, Assistance publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France
| | - Edouard Pertuiset
- Service de rhumatologie, centre hospitalier René-Dubos, Pontoise, France
| | - Jérôme Avouac
- Service de rhumatologie, hôpital Cochin, centre université de Paris Cité, université de Paris, Assistance publique-Hôpitaux de Paris, Paris, France
| | - Pascal Chazerain
- Internal Medicine and Rheumatology Department, Groupe Hospitalier Diaconesses Croix Saint-Simon, 75020 Paris, France
| | - Nicolas Roux
- Rheumatology department, Hôpitaux Privés de Metz - Hôpital Robert-Schuman, Metz, France
| | - Thao Pham
- Department of Rheumatology, Sainte-Marguerite Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - Emmanuelle Dernis
- Department of Rheumatology and Clinical Immunology, General Hospital, Le Mans, France
| | - Yurdagul Uzunhan
- Inserm UMR 1272, Department of Respiratory Medicine, Reference Center for Rare Pulmonary Diseases, Hôpital Avicenne, Université Sorbonne Paris Nord, AP-HP, Bobigny, France
| | - Amélie Servettaz
- Service de médecine interne, maladies infectieuses et immunologie clinique, hôpital Robert-Debré, CHU de Reims, Reims, France
| | - Soumaya El Mahou
- Service de rhumatologie, centre hospitalier de Dron, 59200 Tourcoing, France
| | - Patrice Cacoub
- UMR 959, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Pitié-Salpêtrière Hospital, Sorbonne Université, 75013 Paris, France
| | - Mohamed Hamidou
- Service de médecine interne, PHU3, centre hospitalier universitaire de Nantes - Hôtel-Dieu, 1, place Alexis-Ricordeau, 44093 Nantes, France
| | - Bruno Fautrel
- Inserm UMRS 1136, département de rhumatologie, hôpital Pitié-Salpêtrière, Institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, AP-HP, 75013 Paris, France
| | - Thierry Thomas
- Inserm, SAINBIOSE U1059, service de rhumatologie, université Jean-Monnet Saint-Étienne, CHU de Saint-Étienne, 42023 Saint-Étienne, France
| | - Eric Hachulla
- Department of Internal Medicine and Clinical immunology, Referral Centre for Rare Systemic Auto-immune Diseases North and North-West of France, Lille University School of Medicine, Lille, France
| |
Collapse
|
2
|
Izadi Z, Gianfrancesco MA, Aguirre A, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Lawson‐Tovey S, Kearsley‐Fleet L, Schaefer M, Seet AM, Schmajuk G, Jacobsohn L, Katz P, Rush S, Al‐Emadi S, Sparks JA, Hsu TY, Patel NJ, Wise L, Gilbert E, Duarte‐García A, Valenzuela‐Almada MO, Ugarte‐Gil MF, Ribeiro SLE, de Oliveira Marinho A, de Azevedo Valadares LD, Giuseppe DD, Hasseli R, Richter JG, Pfeil A, Schmeiser T, Isnardi CA, Reyes Torres AA, Alle G, Saurit V, Zanetti A, Carrara G, Labreuche J, Barnetche T, Herasse M, Plassart S, Santos MJ, Rodrigues AM, Robinson PC, Machado PM, Sirotich E, Liew JW, Hausmann JS, Sufka P, Grainger R, Bhana S, Costello W, Wallace ZS, Yazdany J. Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry. ACR Open Rheumatol 2022; 4:872-882. [PMID: 35869686 PMCID: PMC9350083 DOI: 10.1002/acr2.11481] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 05/31/2022] [Indexed: 11/09/2022] Open
Abstract
OBJECTIVE Some patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID-19 ARDS in this population and to create a simple risk score calculator for use in clinical settings. METHODS Data were derived from the COVID-19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID-19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier. RESULTS The study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67-0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%-83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator. CONCLUSION We were able to predict ARDS with good sensitivity using information readily available at COVID-19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID-19 disease progression.
Collapse
Affiliation(s)
| | | | | | | | - Elsa F. Mateus
- Portuguese League Against Rheumatic DiseasesLisbonPortugal
| | - Kimme L. Hyrich
- The University of Manchester and National Institute for Health Research Manchester Biomedical Research Centre, Manchester University and NHS Foundation TrustManchesterUK
| | - Laure Gossec
- INSERM, Sorbonne Universite and Hopital Universitaire Pitie Salpetriere, AP‐HPParisFrance
| | | | - Saskia Lawson‐Tovey
- The University of Manchester and National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust and Manchester Academic Health Science CentreManchesterUK
| | - Lianne Kearsley‐Fleet
- The University of Manchester and Manchester Academic Health Science CentreManchesterUK
| | | | | | - Gabriela Schmajuk
- University of CaliforniaSan Francisco and San Francisco Department of Veterans Affairs Medical Center
| | | | | | | | | | - Jeffrey A. Sparks
- Brigham and Women's Hospital and Harvard Medical SchoolBostonMassachusetts
| | - Tiffany Y‐T Hsu
- Brigham and Women's Hospital and Harvard Medical SchoolBostonMassachusetts
| | - Naomi J. Patel
- Massachusetts General Hospital and Harvard Medical SchoolBoston
| | - Leanna Wise
- University of Southern CaliforniaLos Angeles
| | | | | | | | - Manuel F. Ugarte‐Gil
- Universidad Científica del Sur and Hospital Nacional Guillermo Almenara IrigoyenEsSalud, LimaPeru
| | | | | | | | | | - Rebecca Hasseli
- Justus‐Liebig University Giessen, Campus KerckhoffGiessenGermany
| | | | - Alexander Pfeil
- Jena University Hospital and Friedrich Schiller University JenaJenaGermany
| | - Tim Schmeiser
- Rheumatology im Veedel (Private Practice)CologneGermany
| | | | | | | | | | - Anna Zanetti
- Italian Society for Rheumatology and University of Milano‐BicoccaMilanItaly
| | - Greta Carrara
- Italian Society for Rheumatology and University of Milano‐BicoccaMilanItaly
| | | | - Thomas Barnetche
- FHU ACRONIM, Centre for Autoimmune Systemic Rare Diseases, Bordeaux University HospitalBordeauxFrance
| | - Muriel Herasse
- Filière des Maladies Autoimmunes et Autoinflammatoires Rares, Hôpital Huriez, Centre Hospitalier Universitaire de LilleLilleFrance
| | - Samira Plassart
- Filière des Maladies Autoimmunes et Autoinflammatoires Rares, Hôpital Huriez, Centre Hospitalier Universitaire de LilleLilleFrance
| | - Maria José Santos
- Hospital Garcia de Orta, Almada, Portugal, and Instituto de Medicina Molecular Faculdade Medicina and Rheumatic Diseases Portuguese RegisterLisbonPortugal
| | - Ana Maria Rodrigues
- Rheumatic Diseases Portuguese Register, Sociedade Portuguesa de Reumatologia, Nova Medical School, and Hospital dos LusiadasLisbonPortugal
| | - Philip C. Robinson
- The University of Queensland, Brisbane, Queensland, Australia, and Royal Brisbane and Women's Hospital, Metro North Hospital and Health ServiceHerstonQueenslandAustralia
| | - Pedro M. Machado
- University College London, University College London Hospitals NHS Foundation Trust and Northwick Park Hospital, London North West University Healthcare NHS TrustLondonUK
| | - Emily Sirotich
- McMaster University, Hamilton, Ontario, Canada, and Canadian Arthritis Patient AllianceTorontoOntarioCanada
| | - Jean W. Liew
- Boston University School of MedicineBostonMassachusetts
| | - Jonathan S. Hausmann
- Beth Israel Deaconess Medical Center, Harvard Medical School and Boston Children's HospitalBostonMassachusetts
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Herasse M, Romier M, Hentgen V, Duquesne A, Larbre JP, Maillard H, Pha M, Pillet P, Reumaux H, Truchetet ME, Georgin-Lavialle S, Belot A. Transition de la médecine pédiatrique à la médecine pour adultes dans les maladies autoimmunes et autoinflammatoires rares. Med Sci (Paris) 2022; 38:686-692. [DOI: 10.1051/medsci/2022107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
La commission « Transition » de la filière de santé des maladies auto-immunes et auto-inflammatoires rares a développé des outils et émis des recommandations pour la prise en charge des adolescents et jeunes adultes atteints de ces maladies chroniques évoluant souvent par poussées, durant la période de transition de la médecine pédiatrique vers la médecine pour adultes. L’enjeu de l’adhésion du jeune patient à la poursuite de son parcours de soin dans le système de santé des adultes rend particulièrement importante l’alliance thérapeutique avec son médecin pédiatre puis son médecin pour adultes. Le groupe de travail issu de cette commission a ainsi mené une enquête sur la façon dont les médecins et les jeunes patients perçoivent leur relation durant la période de la transition du suivi médical.
Collapse
|
4
|
Fischer D, Herasse M, Ferreiro A, Barragán-Campos HM, Chiras J, Viollet L, Maugenre S, Leroy JP, Monnier N, Lunardi J, Guicheney P, Fardeau M, Romero NB. Muscle imaging in dominant core myopathies linked or unlinked to the ryanodine receptor 1 gene. Neurology 2007; 67:2217-20. [PMID: 17190947 DOI: 10.1212/01.wnl.0000249151.45200.71] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To characterize the muscle involvement of patients with central core disease (CCD) caused by mutations in the ryanodine receptor 1 gene (RYR1) and to compare these findings with those from patients with core myopathies unlinked to the RYR1 gene. METHODS We performed a systematic muscular imaging assessment in 11 patients with an RYR1 gene mutation and compared these findings with those of 5 patients from two unrelated families with autosomal dominant core myopathies not linked to RYR1, ACTA1, or MYH7 gene loci. RESULTS All patients with RYR1 CCD had a characteristic pattern with predominant involvement of the gluteus maximus, adductor magnus, sartorius, vastus intermediolateralis, soleus, and lateral gastrocnemius muscles. In contrast, muscle CT in the first family not linked to RYR1 showed predominant affection of the gluteus minimus and hamstring muscles, whereas the second family presented with predominant involvement of the gluteus minimus, vastus intermediolateralis, tibialis anterior, and medial gastrocnemius muscles. In addition to muscle imaging data, we present detailed information on the clinical and pathologic findings of these novel phenotypes of core myopathies not linked to RYR1. CONCLUSIONS Our data suggest genetic heterogeneity in autosomal dominant core myopathies and the existence of additional unidentified genes.
Collapse
Affiliation(s)
- D Fischer
- Institut National de la Santé et de la Recherche Médicale U582, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Herasse M, Parain K, Marty I, Monnier N, Kaindl AM, Leroy JP, Richard P, Lunardi J, Romero NB, Ferreiro A. Abnormal Distribution of Calcium-Handling Proteins. J Neuropathol Exp Neurol 2007; 66:57-65. [PMID: 17204937 DOI: 10.1097/nen.0b013e31802d47ce] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Central core disease (CCD) and multi-minicore disease (MmD) are muscle disorders characterized by foci of mitochondria depletion and sarcomere disorganization ("cores") in muscle fibers. Although core myopathies are the most frequent congenital myopathies, their pathogenesis remains elusive and specific diagnostic markers are lacking. Core myopathies are mostly caused by mutations in 2 sarcoplasmic reticulum proteins: the massive Ca-release channel RyR1 or the selenoprotein N (SelN) of unknown function. To search for distinctive markers and to obtain further pathophysiological insight, we identified the molecular defects in 12 core myopathy patients and analyzed the immunolocalization of 6 proteins of the Ca-release complex in their muscle biopsies. In 7 cases with RYR1 mutations (6 CCD, one MmD), RyR1 was depleted from the cores; in contrast, the other proteins of the sarcoplasmic reticulum (calsequestrin, SERCA1/2, and triadin) and the T-tubule (dihydropyridine receptor-alpha1subunit) accumulated within or around the lesions, suggesting an original modification of the Ca-release complex protein arrangement. Conversely, all Ca-related proteins were distributed normally in 5 MmD cases with SelN mutations. Our results provide an appropriate tool to orientate the differential and molecular diagnosis of core myopathies and suggest that different pathophysiological mechanisms lead to core formation in SelN- and in RyR1-related core myopathies.
Collapse
|
6
|
Fischer D, Herasse M, Bitoun M, Barragán-Campos HM, Chiras J, Laforêt P, Fardeau M, Eymard B, Guicheney P, Romero NB. Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. Brain 2006; 129:1463-9. [PMID: 16585051 DOI: 10.1093/brain/awl071] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Centronuclear myopathy (CNM) is a slowly progressive congenital myopathy characterized by abnormal centrally located nuclei in a large number of muscle fibres. Recently, different missense mutations affecting the middle domain of the dynamin 2 (DNM2) have been shown to cause autosomal dominant CNM. In order to better define the phenotype of DNM2-related CNM, we report here on the clinical and muscle imaging findings of 10 patients harbouring DNM2 mutations. DNM2-CNM is characterized by slowly progressive muscular weakness usually beginning in adolescence or early adulthood. In addition to bilateral ptosis, our data show that distal muscle weakness often exceeds proximal involvement. Furthermore, electrophysiological investigations frequently demonstrated signs of mild axonal peripheral nerve involvement, and electromyographical examination may show neuropathic changes in addition to the predominant myopathic changes. These features overlap with findings seen in the phenotype of DNM2-related autosomal dominant Charcot-Marie-Tooth disease type 2B. In all 10 DNM2-CNM patients, muscle computer tomography assessment showed a consistent pattern of muscular involvement and a characteristic temporal course with early and predominant distal muscle involvement, and later affection of the posterior thigh compartment and gluteus minimus muscles. The recognition of this specific imaging pattern of muscle involvement--distinct to the reported patterns in other congenital myopathies--may enable a better selection for direct genetic testing.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Biopsy
- Child
- Dynamin II/genetics
- Humans
- Middle Aged
- Muscle Weakness/diagnostic imaging
- Muscle Weakness/genetics
- Muscle Weakness/pathology
- Muscle, Skeletal/diagnostic imaging
- Muscle, Skeletal/pathology
- Mutation, Missense
- Myopathies, Structural, Congenital/diagnostic imaging
- Myopathies, Structural, Congenital/genetics
- Myopathies, Structural, Congenital/pathology
- Myopathies, Structural, Congenital/physiopathology
- Phenotype
- Tomography, X-Ray Computed
Collapse
Affiliation(s)
- Dirk Fischer
- Institut National de la Santé et de la Recherche Médicale U582, Institut de Myologie IFR14, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Romero NB, Herasse M, Monnier N, Leroy JP, Fischer D, Ferreiro A, Viollet L, Eymard B, Laforêt P, Monges S, Lubieniecki F, Taratuto AL, Guicheney P, Lunardi J, Fardeau M. Clinical and histopathological aspects of central core disease associated and non-associated with RYR1 locus. Acta Myol 2005; 24:70-3. [PMID: 16550918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
We analysed the clinical, histochemical, ultrastructural and genetic data of patients affected by central core disease (CCD) studied during the last 20 years. From a total series of 86 CCD-families, we have identified 46 CCD families with RYR1 mutations (16 autosomal dominant, 8 autosomal recessive, 17 sporadic cases and 5 de novo mutations). Out of the other 40 CCD families, the RyR1 gene was entirely excluded in 7 families, by cDNA sequencing or linkage analysis, indicating a genetic heterogeneity of CCD.
Collapse
Affiliation(s)
- N B Romero
- Institut National de la Santé et de la Recherche Médicale U 582, Association Institut de Myologie, IFR 14, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Herasse M, Spentchian M, Taillandier A, Keppler-Noreuil K, Fliorito ANM, Bergoffen J, Wallerstein R, Muti C, Simon-Bouy B, Mornet E. Molecular study of three cases of odontohypophosphatasia resulting from heterozygosity for mutations in the tissue non-specific alkaline phosphatase gene. J Med Genet 2003; 40:605-9. [PMID: 12920074 PMCID: PMC1735574 DOI: 10.1136/jmg.40.8.605] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
9
|
Spentchian M, Merrien Y, Herasse M, Dobbie Z, Gläser D, Holder SE, Ivarsson SA, Kostiner D, Mansour S, Norman A, Roth J, Stipoljev F, Taillemite JL, van der Smagt JJ, Serre JL, Simon-Bouy B, Taillandier A, Mornet E. Severe hypophosphatasia: characterization of fifteen novel mutations in the ALPL gene. Hum Mutat 2003; 22:105-6. [PMID: 12815606 DOI: 10.1002/humu.9159] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Hypophosphatasia is an inherited disorder characterized by defective bone mineralization and deficiency of serum and tissue liver/bone/kidney alkaline phosphatase (L/B/K ALP) activity. We report the characterization of ALPL gene mutations in a series of 11 families from various origins affected by perinatal and infantile hypophosphatasia. Sixteen distinct mutations were found, fifteen of them not previously reported: M45V, G46R, 388-391delGTAA, 389delT, T131I, G145S, D172E, 662delG, G203A, R255L, 876-881delAGGGGA, 962delG, E294K, E435K, and A451T. This confirms that severe hypophosphatasia is due to a large spectrum of mutations in Caucasian populations.
Collapse
Affiliation(s)
- M Spentchian
- Centre d'Etudes de Biologie Prénatal-SESEP, Université de Versailles-Saint Quentin en Yvelines, Versailles, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Spencer MJ, Guyon JR, Sorimachi H, Potts A, Richard I, Herasse M, Chamberlain J, Dalkilic I, Kunkel LM, Beckmann JS. Stable expression of calpain 3 from a muscle transgene in vivo: immature muscle in transgenic mice suggests a role for calpain 3 in muscle maturation. Proc Natl Acad Sci U S A 2002; 99:8874-9. [PMID: 12084932 PMCID: PMC124391 DOI: 10.1073/pnas.132269299] [Citation(s) in RCA: 79] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/06/2002] [Indexed: 11/18/2022] Open
Abstract
Limb-girdle muscular dystrophy, type 2A (LGMD 2A), is an autosomal recessive disorder that causes late-onset muscle-wasting, and is due to mutations in the muscle-specific protease calpain 3 (C3). Although LGMD 2A would be a feasible candidate for gene therapy, the reported instability of C3 in vitro raised questions about the potential of obtaining a stable, high-level expression of C3 from a transgene in vivo. We have generated transgenic (Tg) mice with muscle-specific overexpression of full-length C3 or C3 isoforms, which arise from alternative splicing, to test whether stable expression of C3 transgenes could occur in vivo. Unexpectedly, we found that full-length C3 can be overexpressed at high levels in vivo, without toxicity. In addition, we found that Tg expressing C3 lacking exon 6, an isoform expressed embryonically, have muscles that resemble regenerating or developing muscle. Tg expressing C3 lacking exon 15 shared this morphology in the soleus, but not other muscles. Assays of inflammation or muscle membrane damage indicated that the Tg muscles were not degenerative, suggesting that the immature muscle resulted from a developmental block rather than degeneration and regeneration. These studies show that C3 can be expressed stably in vivo from a transgene, and indicate that alternatively spliced C3 isoforms should not be used in gene-therapy applications because they impair proper muscle development.
Collapse
Affiliation(s)
- M J Spencer
- Department of Pediatrics, University of California, Los Angeles, CA 90095, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Stockholm D, Herasse M, Marchand S, Praud C, Roudaut C, Richard I, Sebille A, Beckmann JS. Calpain 3 mRNA expression in mice after denervation and during muscle regeneration. Am J Physiol Cell Physiol 2001; 280:C1561-9. [PMID: 11350751 DOI: 10.1152/ajpcell.2001.280.6.c1561] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Lack of functional calpain 3 in humans is a cause of limb girdle muscular dystrophy, but the function(s) of calpain 3 remain(s) unknown. Special muscle conditions in which calpain 3 is downregulated could yield valuable clues to the understanding of its function(s). We monitored calpain 3 mRNA amounts by quantitative RT-PCR and compared them with those of α-skeletal actin mRNA in mouse leg muscles for different types of denervation and muscle injury. Intact muscle denervation reduced calpain 3 mRNA expression by a factor of 5 to 10, while α-skeletal actin mRNA was reduced in a slower and less extensive manner. Muscle injury (denervation-devascularization), which leads to muscle degeneration and regeneration, induced a 20-fold decrease in the mRNA level of both calpain 3 and α-skeletal actin. Furthermore, whereas in normal muscle and intact denervated muscle, the full-length transcript is the major calpain 3 mRNA, in injured muscle, isoforms lacking exon 6 are predominant during the early regeneration process. These data suggest that muscle condition determines the specific calpain 3 isoform pattern of expression and that calpain 3 expression is downregulated by denervation.
Collapse
Affiliation(s)
- D Stockholm
- Généthon, CNRS URA 1922-1923, 1 bis rue de l'Internationale, BP 60, 91002 Evry, France
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Richard I, Roudaut C, Marchand S, Baghdiguian S, Herasse M, Stockholm D, Ono Y, Suel L, Bourg N, Sorimachi H, Lefranc G, Fardeau M, Sébille A, Beckmann JS. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. J Cell Biol 2000; 151:1583-90. [PMID: 11134085 PMCID: PMC2150676 DOI: 10.1083/jcb.151.7.1583] [Citation(s) in RCA: 141] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Calpain 3 is known as the skeletal muscle-specific member of the calpains, a family of intracellular nonlysosomal cysteine proteases. It was previously shown that defects in the human calpain 3 gene are responsible for limb girdle muscular dystrophy type 2A (LGMD2A), an inherited disease affecting predominantly the proximal limb muscles. To better understand the function of calpain 3 and the pathophysiological mechanisms of LGMD2A and also to develop an adequate model for therapy research, we generated capn3-deficient mice by gene targeting. capn3-deficient mice are fully fertile and viable. Allele transmission in intercross progeny demonstrated a statistically significant departure from Mendel's law. capn3-deficient mice show a mild progressive muscular dystrophy that affects a specific group of muscles. The age of appearance of myopathic features varies with the genetic background, suggesting the involvement of modifier genes. Affected muscles manifest a similar apoptosis-associated perturbation of the IkappaBalpha/nuclear factor kappaB pathway as seen in LGMD2A patients. In addition, Evans blue staining of muscle fibers reveals that the pathological process due to calpain 3 deficiency is associated with membrane alterations.
Collapse
MESH Headings
- Animals
- Apoptosis
- Calpain/chemistry
- Calpain/deficiency
- Calpain/genetics
- Calpain/metabolism
- Creatine Kinase/metabolism
- Crosses, Genetic
- DNA-Binding Proteins/metabolism
- Evans Blue
- Female
- Fertility
- Gene Deletion
- Gene Targeting
- Genotype
- I-kappa B Proteins
- Male
- Mice
- Mice, Knockout
- Muscle Fibers, Skeletal/enzymology
- Muscle Fibers, Skeletal/metabolism
- Muscle Fibers, Skeletal/pathology
- Muscle, Skeletal/enzymology
- Muscle, Skeletal/metabolism
- Muscle, Skeletal/pathology
- Muscular Dystrophies/enzymology
- Muscular Dystrophies/genetics
- Muscular Dystrophies/metabolism
- Muscular Dystrophies/pathology
- NF-KappaB Inhibitor alpha
- NF-kappa B/metabolism
- Phenotype
- RNA, Messenger/analysis
- RNA, Messenger/genetics
- Sarcolemma/pathology
- Signal Transduction
Collapse
Affiliation(s)
| | | | | | - Stephen Baghdiguian
- Laboratoire de Dynamique Moléculaire des Interactions Membranaires, CNRS-UMR 5539
| | | | | | - Yasuko Ono
- Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo 113-8657, Japan
| | | | | | - Hiroyuki Sorimachi
- Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo 113-8657, Japan
| | - Gérard Lefranc
- Laboratoire d'ImmunoGénétique Moléculaire, Institut de Génétique Humaine, CNRS UPR 1142, Université Montpellier 2, 34095 Montpellier Cedex 5, France
| | - Michel Fardeau
- Institut de Myologie, Hôpital Pitié-Salpétrière, 75013 Paris, France
| | - Alain Sébille
- Atelier de Régénération Neuromusculaire, Faculté de Médecine Saint Antoine, 75012 Paris, France
| | - Jacques S. Beckmann
- Généthon, CNRS URA 1922–1923, 91000 Évry, France
- Centre National de Genotypage, 91057 Evry, France
| |
Collapse
|
13
|
Fougerousse F, Bullen P, Herasse M, Lindsay S, Richard I, Wilson D, Suel L, Durand M, Robson S, Abitbol M, Beckmann JS, Strachan T. Human-mouse differences in the embryonic expression patterns of developmental control genes and disease genes. Hum Mol Genet 2000; 9:165-73. [PMID: 10607827 DOI: 10.1093/hmg/9.2.165] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Our understanding of early human development has been impeded by the general difficulty in obtaining suitable samples for study. As a result, and because of the extraordinarily high degree of evolutionary conservation of many developmentally important genes and developmental pathways, great reliance has been placed on extrapolation from animal models of development, principally the mouse. However, the strong evolutionary conservation of coding sequence for developmentally important genes does not necessarily mean that their expression patterns are as highly conserved. The very recent availability of human embryonic samples for gene expression studies has now permitted for the first time an assessment of the degree to which we can confidently extrapolate from studies of rodent gene expression patterns. We have found significant human-mouse differences in embryonic expression patterns for a variety of genes. We present detailed data for two illustrative examples. Wnt7a, a very highly conserved gene known to be important in early development, shows significant differences in spatial and temporal expression patterns in the developing brain (midbrain, telencephalon) of man and mice. CAPN3, the locus for LGMD2A limb girdle muscular dystrophy, and its mouse orthologue differ extensively in expression in embryonic heart, lens and smooth muscle. Our study also shows how molecular analyses, while providing explanations for the observed differences, can be important in providing insights into mammalian evolution.
Collapse
Affiliation(s)
- F Fougerousse
- URA-CNRS 1922-Généthon, 1 rue de l'Internationale, BP 60, 91002 Evry, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Herasse M, Ono Y, Fougerousse F, Kimura E, Stockholm D, Beley C, Montarras D, Pinset C, Sorimachi H, Suzuki K, Beckmann JS, Richard I. Expression and functional characteristics of calpain 3 isoforms generated through tissue-specific transcriptional and posttranscriptional events. Mol Cell Biol 1999; 19:4047-55. [PMID: 10330145 PMCID: PMC104364 DOI: 10.1128/mcb.19.6.4047] [Citation(s) in RCA: 92] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/1998] [Accepted: 03/03/1999] [Indexed: 11/20/2022] Open
Abstract
Calpain 3 is a nonlysosomal cysteine protease whose biological functions remain unknown. We previously demonstrated that this protease is altered in limb girdle muscular dystrophy type 2A patients. Preliminary observations suggested that its gene is subjected to alternative splicing. In this paper, we characterize transcriptional and posttranscriptional events leading to alterations involving the NS, IS1, and IS2 regions and/or the calcium binding domains of the mouse calpain 3 gene (capn3). These events can be divided into three groups: (i) splicing of exons that preserve the translation frame, (ii) inclusion of two distinct intronic sequences between exons 16 and 17 that disrupt the frame and would lead, if translated, to a truncated protein lacking domain IV, and (iii) use of an alternative first exon specific to lens tissue. In addition, expression of these isoforms seems to be regulated. Investigation of the proteolytic activities and titin binding abilities of the translation products of some of these isoforms clearly indicated that removal of these different protein segments affects differentially the biochemical properties examined. In particular, removal of exon 6 impaired the autolytic but not fodrinolytic activity and loss of exon 16 led to an increased titin binding and a loss of fodrinolytic activity. These results are likely to impact our understanding of the pathophysiology of calpainopathies and the development of therapeutic strategies.
Collapse
MESH Headings
- Alternative Splicing
- Animals
- Brain/metabolism
- Calpain/genetics
- Calpain/metabolism
- Carrier Proteins/metabolism
- Cells, Cultured
- Cloning, Molecular
- Connectin
- DNA Primers
- Embryo, Mammalian/anatomy & histology
- Embryo, Mammalian/metabolism
- Humans
- In Situ Hybridization
- Introns
- Isoenzymes
- Lens, Crystalline/anatomy & histology
- Lens, Crystalline/metabolism
- Mice
- Mice, Inbred BALB C
- Microfilament Proteins/metabolism
- Models, Genetic
- Muscle Proteins/metabolism
- Muscle, Skeletal/metabolism
- Muscle, Smooth/metabolism
- Myocardium/metabolism
- Peptide Fragments/metabolism
- Protein Kinases/metabolism
- RNA Processing, Post-Transcriptional
- Rats
- Reverse Transcriptase Polymerase Chain Reaction
- Time Factors
- Tissue Distribution
- Transcription, Genetic
Collapse
Affiliation(s)
- M Herasse
- Généthon, CNRS URA 1922, 91000 Evry, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Herasse M, Baghdiguian S, Fougerousse F, Martin M, Stockholm D, Beckmann JS, Lefranc G, Richard I. Calpaïne 3 et dystrophie musculaire des ceintures type 2A. Med Sci (Paris) 1999. [DOI: 10.4267/10608/1286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|